VITAMIN D STATUS AND CONSEQUENCES OF LONG TERM
SUPPLEMENTATION WITH ORAL NATIVE VITAMIN D3 ON THE
SEVERITY OF PRIMARY HYPERPARATHYROIDISM - THE
ROMANIAN EXPERIENCE
DANIEL GRIGORIE 1,2*, DIANA COLES 1, ANDRA CARAGHEORGHEOPOL 1, ALINA ŞUCALIUC 1,2
1“C. I. Parhon” National Institute of Endocrinology, Bucharest, Romania
2Department of Endocrinology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
*corresponding author: grigorie_d@yahoo.com
Download Full Article

Abstract:
Primary hyperparathyroidism is a common general endocrine disorder everywhere but the clinical presentation differs between
western and other countries, probably because of the different prevalence of vitamin D deficiency and its consequences. The
study objective was first to compare the prevalence of both vitamin D insufficiency and deficiency between primary hyperparathyroidism
(PHPT) patients and controls and to assess the association between 25hydroxi-vitamin D (25OHD) levels and
PHPT severity (osteoporosis, fractures, nephrolithiasis, serum and urine calcium, serum PTH, bone turnover markers, bone
mineral density (BMD)) and secondly to evaluate the effects of vitamin D repletion. In a cohort of 221 patients with PHPT
(mean PTH 317.2 pg/mL; mean Ca 11.4 mg/dL) it was found a significantly lower mean serum 25OHD (13.42 ng/mL vs
17.66 ng/mL) and a significantly higher (34.72%) prevalence of severe vitamin D deficiency (< 10 ng/mL) than in osteoporosis
controls (12.83%). Low serum 25OHD was associated with higher serum levels of calcium, PTH and alkaline phosphatase
but not with the clinical severity. Supplementing vitamin D in mild primary hyperparathyroidism is safe, as it does not increase
serum calcium and significantly reduces iPTH levels.

Top